579 related articles for article (PubMed ID: 22854138)
1. Urodynamic effects of transrectal intraprostatic Ona botulinum toxin A injections for symptomatic benign prostatic hyperplasia.
de Kort LM; Kok ET; Jonges TN; Rosier PF; Bosch JL
Urology; 2012 Oct; 80(4):889-93. PubMed ID: 22854138
[TBL] [Abstract][Full Text] [Related]
2. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2010 Mar; 183(3):1092-7. PubMed ID: 20092847
[TBL] [Abstract][Full Text] [Related]
3. Relief by botulinum toxin of lower urinary tract symptoms owing to benign prostatic hyperplasia: early and long-term results.
Brisinda G; Cadeddu F; Vanella S; Mazzeo P; Marniga G; Maria G
Urology; 2009 Jan; 73(1):90-4. PubMed ID: 18995889
[TBL] [Abstract][Full Text] [Related]
4. Prostate botulinum A toxin injection--an alternative treatment for benign prostatic obstruction in poor surgical candidates.
Kuo HC
Urology; 2005 Apr; 65(4):670-4. PubMed ID: 15833506
[TBL] [Abstract][Full Text] [Related]
5. Sustained beneficial effects of intraprostatic botulinum toxin type A on lower urinary tract symptoms and quality of life in men with benign prostatic hyperplasia.
Chuang YC; Chiang PH; Yoshimura N; De Miguel F; Chancellor MB
BJU Int; 2006 Nov; 98(5):1033-7; discussion 1337. PubMed ID: 16956361
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of silodosin for relieving benign prostatic obstruction: prospective pressure flow study.
Matsukawa Y; Gotoh M; Komatsu T; Funahashi Y; Sassa N; Hattori R
J Urol; 2009 Dec; 182(6):2831-5. PubMed ID: 19837428
[TBL] [Abstract][Full Text] [Related]
7. Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.
Sacco E; Bientinesi R; Marangi F; Totaro A; D'Addessi A; Racioppi M; Pinto F; Vittori M; Bassi P
BJU Int; 2012 Dec; 110(11 Pt C):E837-44. PubMed ID: 22712582
[TBL] [Abstract][Full Text] [Related]
8. Transurethral ethanol injection therapy of benign prostatic hyperplasia: four-year follow-up.
Sakr M; Eid A; Shoukry M; Fayed A
Int J Urol; 2009 Feb; 16(2):196-201. PubMed ID: 19054163
[TBL] [Abstract][Full Text] [Related]
9. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up?
Rigatti L; Naspro R; Salonia A; Centemero A; Ghezzi M; Guazzoni G; Briganti A; Rigatti P; Montorsi F
Urology; 2006 Jun; 67(6):1193-8. PubMed ID: 16750253
[TBL] [Abstract][Full Text] [Related]
10. The application of botulinum toxin in the prostate.
Chuang YC; Chancellor MB
J Urol; 2006 Dec; 176(6 Pt 1):2375-82. PubMed ID: 17085104
[TBL] [Abstract][Full Text] [Related]
11. Is botulinum neurotoxin type A (BoNT-A) a novel therapy for lower urinary tract symptoms due to benign prostatic enlargement? A review of the literature.
Oeconomou A; Madersbacher H; Kiss G; Berger TJ; Melekos M; Rehder P
Eur Urol; 2008 Oct; 54(4):765-75. PubMed ID: 18571306
[TBL] [Abstract][Full Text] [Related]
12. Intraprostatic and bladder-neck injection of botulinum A toxin in treatment of males with bladder-neck dyssynergia: a pilot study.
Lim SK; Quek PL
Eur Urol; 2008 Mar; 53(3):620-5. PubMed ID: 17950522
[TBL] [Abstract][Full Text] [Related]
13. The 12-year symptomatic outcome of transurethral resection of the prostate for patients with lower urinary tract symptoms suggestive of benign prostatic obstruction compared to the urodynamic findings before surgery.
Masumori N; Furuya R; Tanaka Y; Furuya S; Ogura H; Tsukamoto T
BJU Int; 2010 May; 105(10):1429-33. PubMed ID: 19863522
[TBL] [Abstract][Full Text] [Related]
14. Intraprostatic botulinum toxin type "A" injection in patients with benign prostatic hyperplasia and unsatisfactory response to medical therapy: A randomized, double-blind, controlled trial using urodynamic evaluation.
Totaro A; Pinto F; Pugliese D; Vittori M; Racioppi M; Foschi N; Bassi PF; Sacco E
Neurourol Urodyn; 2018 Mar; 37(3):1031-1038. PubMed ID: 28840969
[TBL] [Abstract][Full Text] [Related]
15. Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport.
Nikoobakht M; Daneshpajooh A; Ahmadi H; Namdari F; Rezaeidanesh M; Amini S; Pourmand G
Scand J Urol Nephrol; 2010 Apr; 44(3):151-7. PubMed ID: 20201752
[TBL] [Abstract][Full Text] [Related]
16. Bipolar plasmakinetic transurethral resection of prostate in 132 consecutive patients with large gland: three-year follow-up results.
Zhu G; Xie C; Wang X; Tang X
Urology; 2012 Feb; 79(2):397-402. PubMed ID: 22035765
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy.
Kuo HC; Liu HT
Scand J Urol Nephrol; 2009; 43(3):206-11. PubMed ID: 19308807
[TBL] [Abstract][Full Text] [Related]
18. Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial.
Dmochowski R; Roehrborn C; Klise S; Xu L; Kaminetsky J; Kraus S
J Urol; 2013 Jan; 189(1 Suppl):S135-40. PubMed ID: 23234619
[TBL] [Abstract][Full Text] [Related]
19. Botulinum toxin for the treatment of lower urinary tract symptoms due to benign prostatic hyperplasia.
Antunes AA; Srougi M; Coelho RF; de Campos Freire G
Nat Clin Pract Urol; 2007 Mar; 4(3):155-60. PubMed ID: 17347660
[TBL] [Abstract][Full Text] [Related]
20. The relationship of the International Prostate Symptom Score and objective parameters for diagnosing bladder outlet obstruction. Part I: when statistics fail.
Wadie BS; Ibrahim EH; de la Rosette JJ; Gomha MA; Ghoneim MA
J Urol; 2001 Jan; 165(1):32-4. PubMed ID: 11125357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
